Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia

被引：6

作者：

Silla, Lucia ^{[1
]}

Dulley, Frederico ^{[2
]}

Saboya, Rosaura ^{[2
]}

Kerbauy, Fabio ^{[3
,4
]}

Arantes, Adriano de Moraes ^{[5
]}

Pezzi, Annelise ^{[1
]}

Gross, Luisa Grave ^{[6
]}

Paton, Eduardo ^{[7
]}

Hamerschlak, Nelson ^{[3
,4
]}

机构：

[1] Univ Fed Rio Grande do Sul, Cellular Therapy Program HCPA, Porto Alegre, RS, Brazil

[2] Hosp Ingles, Bone Marrow Transplantat Unit, Sao Paulo, Brazil

[3] Hosp Albert Einstein, Hematol & Bone Marrow Transplantat Unit, Sao Paulo, Brazil

[4] Univ Fed Sao Paulo, Sao Paulo, Brazil

[5] Hosp Araujo Jorge, Hematol & Bone Marrow Transplantat Unit, Goiania, Go, Brazil

[6] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil

[7] Hosp Canc Barretos, Bone Marrow Transplantat Unit, Barretos, Brazil

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2017年 / 98卷 / 02期

关键词：

acute myeloid leukemia; guideline; bone marrow transplantation; hematopoietic stem cell transplantation; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; 1ST REMISSION; RETROSPECTIVE ANALYSIS; EUROPEAN LEUKEMIANET; UNRELATED DONORS; MOBILIZED BLOOD; OLDER PATIENT; RISK SCORE;

D O I：

10.1111/ejh.12808

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction/Objectives: Acute myeloid leukemia (AML) accounts for 90% of all cases of acute leukemia in adults. In Brazil, the mortality from myeloid leukemia is 1.74/100 000 men and 1.37/100 000 women. Our aim was to review and update guidelines of the Brazilian Society of Bone Marrow Transplantation on indications of hematopoietic stem cell transplantation (HSCT) for the treatment AML. Conclusions: (i) Allo-HSCT is recommended for high-risk AML (IA); (ii) allo-HSCT is recommended for AML of intermediate risk (IA); (iii) allo-HSCT is recommended for AML relapsed/refractory (C4); (iv) auto-HSCT is recommended for AML after 1 consolidation (C4); (v) auto-HSCT is recommended for AML in CR1 (higher than QT in the Brazilian experience) (C4); (vi) auto-HSCT is accepted for AML M3 in second molecular complete remission (2B); (vii) peripheral blood instead of Bone Marrow HSC for advanced disease (2A); (viii) recommended conditioning protocols: Bu-Cy/Bu-Mel, Bu-Flu, TBI-Cy. In umbilical cord HSCT, consider ATG-based protocols (2A); (ix) allogeneic HSCT for the treatment of AML can be used in patients between 60 and 80 yr with good performance status and the absence of significant comorbidities (C4).

引用

页码：177 / 183

页数：7

共 63 条

[1] Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life [J].

Alatrash, Gheath ;

de Lima, Marcos ;

Hamerschlak, Nelson ;

Pelosini, Matteo ;

Wang, Xuemei ;

Xiao, Lianchun ;

Kerbauy, Fabio ;

Chiattone, Alexandre ;

Rondon, Gabriela ;

Qazilbash, Muzaffar H. ;

Giralt, Sergio A. ;

Silva, Leandro de Padua ;

Hosing, Chitra ;

Kebriaei, Partow ;

Zhang, Weiqing ;

Nieto, Yago ;

Saliba, Rima M. ;

Champlin, Richard E. ;

Andersson, Borje S. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (10) :1490-1496

[2] Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS [J].

Andersson, Borje S. ;

de Lima, Marcos ;

Thall, Peter F. ;

Wang, Xuemei ;

Couriel, Daniel ;

Korbling, Martin ;

Roberson, Soonja ;

Giralt, Sergio ;

Pierre, Betty ;

Russell, James A. ;

Shpall, Elizabeth J. ;

Jones, Roy B. ;

Champlin, Richard E. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (06) :672-684

[3]

Appelbaum FR, 2008, HEMATOL-AM SOC HEMAT, V2008, P412, DOI DOI 10.1182/ASHEDUCATI0N-2008.1.412

[4] Preparative Regimens and Ageism [J].

Appelbaum, Frederick R. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (10) :1419-1420

[5]

Atlas on- line of the INCa, 2014, ATLAS ON LINE INCA O

Basara, N. ;

Schulze, A. ;

Wedding, U. ;

Mohren, M. ;

Gerhardt, A. ;

Junghanss, C. ;

Peter, N. ;

Doelken, G. ;

Becker, C. ;

Heyn, S. ;

Kliem, C. ;

Lange, T. ;

Krahl, R. ;

Poenisch, W. ;

Fricke, H-J ;

Sayer, H. G. ;

Al-Ali, H. ;

Kamprad, F. ;

Niederwieser, D. .

LEUKEMIA, 2009, 23 (04) :635-640

[7] Nonbiological factors affecting survival in younger patients with acute myeloid leukemia [J].

Borate, Uma Madhav ;

Mineishi, Shin ;

Costa, Luciano Jose .

CANCER, 2015, 121 (21) :3877-3884

[8] Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: A matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide [J].

Bredeson, Christopher N. ;

Zhang, Mei-Jie ;

Agovi, Manza-A. ;

Bacigalupo, Andrea ;

Bahlis, Nizar J. ;

Ballen, Karen ;

Brown, Christopher ;

Chaudhry, M. Ahsan ;

Horowitz, Mary M. ;

Kurian, Seira ;

Quinlan, Diana ;

Muehlenbien, Catherine E. ;

Russell, James A. ;

Savoie, Lynn ;

Rizzo, J. Douglas ;

Stewart, Douglas A. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (09) :993-1003

[9]

Callera Fernando, 2015, Rev. Bras. Hematol. Hemoter., V37, P07, DOI 10.1016/j.bjhh.2014.11.011

[10] Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients [J].

Campregher, Paulo Vidal ;

Hamerschlak, Nelson ;

Renzi Colturato, Vergilio Antonio ;

Mauad, Marcos Augusto ;

de Souza, Mair Pedro ;

da Silva Bouzas, Luis Fernando ;

Tavares, Rita de Cassia B. ;

Barros, Jose Carlos ;

Chiattone, Ricardo ;

Paz, Alessandra ;

Silla, Lucia ;

Vigorito, Afonso Celso ;

Miranda, Eliane ;

Moreira Funke, Vaneuza Araujo ;

Flowers, Mary Evelyn .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (05) :421-425

← 1 2 3 4 5 6 7 →